Pilot Study of High Risk Lung Cancer Screening



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:40 - 82
Updated:9/27/2018
Start Date:August 10, 2016
End Date:October 1, 2020
Contact:Erin Hirsch
Email:ERIN.HIRSCH@UCDENVER.EDU
Phone:303-724-1658

Use our guide to learn which trials are right for you!

A Prospective Pilot Study of Lung Cancer Screening in Patients at High Risk for Lung Cancer Who Do Not Meet Current Screening Guidelines

This study is a prospective trial of 200 individuals at high risk for lung cancer who are not
eligible for lung cancer screening under current screening guidelines.

This study is a prospective trial of 200 individuals at high risk for lung cancer who are not
eligible for lung cancer screening under current screening guidelines. Potential subject's 6
yr lung cancer risk must exceed 1.5% by the Tammamagi PLCO2012m calculator. Patients will
undergo a non contrast CT chest for lung cancer screening. This cutoff should encompass in
excess of 80% of all lung cancer cases (10). However, in patients 78-82 years old we will set
the 6 yr lung cancer risk threshold at 4.0% as these patients will typically have other
competing risks of death and this may potentially limit screening benefit in these older
individuals.

Inclusion Criteria:

1. Adult 40-82 yrs of age.

2. Presenting for lung cancer screening evaluation.

3. Calculated 6 yr lung cancer risk >1.5% for patients 40-77 years of age or >4% for
patients 78-82 years of age.

4. Able and willing to provide informed consent.

Exclusion Criteria:

1. Eligible for clinically indicated lung cancer screening (55-80 yr old, >30 pky smoking
history, still smoking or quit smoking within the last 15 yr).

2. Chest CT performed within the last year.

3. Life expectancy less than 6 months.

4. Symptoms clinically consistent with lung cancer.

5. Unable or unwilling to undergo treatment for lung cancer.

6. Any individual who does not give oral and written consent for participation.
We found this trial at
1
site
Denver, Colorado 80262
Principal Investigator: Jeffrey Sippel, MD
Phone: 303-724-1658
?
mi
from
Denver, CO
Click here to add this to my saved trials